Readystate Asset Management’s Blueprint Medicines BPMC Stock Holding History

Readystate Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-329,831	Closed	-$42.3M	–	411
2025 Q2	$42.3M	Buy	+329,831	New	+$34.3M	1.29%	12
2024 Q4	–	Sell	-56,500	Closed	-$5.23M	–	625
2024 Q3	$5.23M	Buy	+56,500	New	+$5.61M	0.1%	285
2024 Q1	–	Sell	-40,028	Closed	-$3.69M	–	895
2023 Q4	$3.69M	Buy	+40,028	New	+$2.59M	0.13%	167

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Readystate Asset Management's BPMC Position: Q3 2025 in Review

Readystate Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 329,831 shares — an estimated $42.3M sold.

Readystate Asset Management first reported a position in BPMC in Q4 2023 and held it in 3 quarters. The position peaked at $42.3M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Readystate Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Readystate Asset Management sold 329,831 Blueprint Medicines shares in Q3 2025, an estimated $42.3M.
Readystate Asset Management first reported a position in Blueprint Medicines in Q4 2023 and held it in 3 quarters.
Readystate Asset Management's Blueprint Medicines position peaked at $42.3M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Readystate Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.